Tempus AI, Inc. TEM
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- +22.30%
- 1 year
- -16.29%
- Open
- 73.49
- Prev close
- 77.84
- Mkt cap
- 13.16B
- Vol
- 10.46M
- Avg vol
- 6.82M
- EPS
- -1.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 70.86
- High
- 76.65
- Forward P/E
- -1556.80
- Beta
- 3.54
- Short ratio
- 3.32
- Inst. own
- 58.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 70.58
- 200-d avg
- 56.92
- 1y target
- 75.06
5D chart
Events in this range
- Oct 26, 2026Rating: BTIG · Buy → Buy
- Oct 26, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (158)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:50 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:45 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:15 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:15 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:25 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:45 AM | 1 day ago |
| RSI: Oversold | Oct 30, 10:10 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| RSI: Oversold | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:40 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:35 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:05 PM | 4 days ago |
| RSI: Overbought | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:50 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
News
16 hours ago defenseworld.net
Tempus AI (NASDAQ:TEM) Stock: Insider Eric Lefkofsky Sells 250,000 Shares
Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $70.36, for…
1 day ago zacks.com
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.
4 days ago 247wallst.com
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the…
5 days ago zacks.com
Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
5 days ago benzinga.com
Tempus AI's XR Assay Receives EU Certification As A Class C In Vitro Diagnostic Device
The certification covers Tempus’ quality management system for "next-generation sequencing devices for cancer genomic profiling to support clinical management."xR detects gene rearrangements and…
5 days ago businesswire.com
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in…
-
5 days ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $68
HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $66 to $68.
1 week ago seekingalpha.com
Tempus AI: Less Risky Than When I Said Buy
Tempus AI is now a higher-conviction Buy after resolving prior concerns on MRD ownership and cash flow, with adjusted EBITDA turning positive. The Personalis acquisition secures MRD capabilities,…
-
1 week ago benzinga.com
Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio
Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…
1 week ago businesswire.com
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology…
1 week ago businesswire.com
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb…
1 week ago seekingalpha.com
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction with Big Pharma partnerships. TEM's differentiated model leverages AI-driven…
1 week ago etftrends.com
How Tempus AI Built a Defensible Data Moat in Precision Healthcare
As access to powerful general-purpose AI models expands, access alone offers limited differentiation. In precision healthcare, competitive advantage can come from combining proprietary clinical data,…
1 week ago gurufocus.com
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung c
1 week ago zacks.com
Here's How Tempus AI Demonstrates Improving Operating Leverage
TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
1 week ago marketbeat.com
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to…
-
1 week ago benzinga.com
Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026
Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology imagesTempus AI, Inc. (NASDAQ:TEM)…
1 week ago businesswire.com
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer…
2 weeks ago businesswire.com
Tempus to Report Third Quarter 2026 Financial Results on November 2
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third…
2 weeks ago businesswire.com
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™…
-
2 weeks ago benzinga.com
Canaccord Genuity Maintains Buy on Tempus AI, Raises Price Target to $95
Canaccord Genuity analyst Kyle Mikson maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $80 to $95.
2 weeks ago zacks.com
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
2 weeks ago benzinga.com
Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’
Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'
3 weeks ago zacks.com
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.
3 weeks ago benzinga.com
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for…
3 weeks ago benzinga.com
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
3 weeks ago gurufocus.com
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a
3 weeks ago benzinga.com
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
3 weeks ago benzinga.com
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
1 month ago benzinga.com
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92
Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $65 to $92.
-
1 month ago benzinga.com
Tempus AI Receives 510(k) Clearance From FDA For Tempus ECG-MR, AI Product That Analyzes Standard 12-Lead Resting Ecgs To Detect Signs Associated With Undiagnosed Mitral Regurgitation
ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular diseaseTempus AI, Inc. (NASDAQ:TEM) today announced it has received…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
1 month ago benzinga.com
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new…
1 month ago benzinga.com
This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Wall Street initiated coverage on XRN, TEM, NNE, SECZ with ratings from Neutral to Buy and price targets of $21.20-$75.
-
1 month ago benzinga.com
Goldman Sachs Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $75
Goldman Sachs analyst Evie Koslosky initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $75.
1 month ago benzinga.com
Why Is Tempus AI Stock Falling Friday?
Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
1 month ago benzinga.com
Nasdaq 100 Rallies as Oil Slides, Yields Retreat: Stock Market Today
Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and…
1 month ago benzinga.com
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
-
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago benzinga.com
Novo Nordisk, Anthropic Team Up For AI Drug Research
Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement responsible data governance standards.
1 month ago benzinga.com
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
1 month ago benzinga.com
Nvidia, Snowflake, Chubb And A Health Care Stock On CNBC’s ‘Final Trades’
CNBC’s final trades: Joshua Brown picked Snowflake, Bill Baruch chose Tempus AI, Malcolm Ethridge favored Chubb, and Stephanie Link recommended Nvidia.
-
1 month ago benzinga.com
Tempus AI Announces Initiative To Build Research Platform Containing 100K Whole Genomes Linked To Longitudinal Clinical Information Over Next Several Years
The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million GenomesTempus AI, Inc.…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $66
HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $56 to $66.
-
1 month ago benzinga.com
Tempus AI Selected By Advanced Research Projects Agency For Health To Be Awarded $9.5M For First Autonomous Clinical AI Agent
Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human…
-
1 month ago benzinga.com
UBS Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $70
UBS analyst Doug Schenkel initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $70.
-
1 month ago benzinga.com
Rothschild & Co Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Rothschild & Co analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $67.
-
1 month ago benzinga.com
Roth Capital Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Roth Capital analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $67.
1 month ago benzinga.com
Tempus AI's Data Business Is Priced Like a Vendor, Not a Platform, Analyst Says
Tempus AI receives an Overweight rating and $80 price target from Cantor Fitzgerald, which sees significant upside from its data and applications business.